Header Logo

Connection

Matthew Meriggioli to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Matthew Meriggioli has written about Antibodies, Monoclonal.
Matthew Meriggioli
Connection Strength
0.051
Antibodies, Monoclonal
  1. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.